IL97709A - Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis - Google Patents
Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosisInfo
- Publication number
- IL97709A IL97709A IL9770991A IL9770991A IL97709A IL 97709 A IL97709 A IL 97709A IL 9770991 A IL9770991 A IL 9770991A IL 9770991 A IL9770991 A IL 9770991A IL 97709 A IL97709 A IL 97709A
- Authority
- IL
- Israel
- Prior art keywords
- multiple sclerosis
- directed
- medicament
- preparation
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50255990A | 1990-03-30 | 1990-03-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
IL97709A0 IL97709A0 (en) | 1992-06-21 |
IL97709A true IL97709A (en) | 2005-05-17 |
Family
ID=23998362
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL9770991A IL97709A (en) | 1990-03-30 | 1991-03-28 | Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis |
IL165071A IL165071A (en) | 1990-03-30 | 1991-03-28 | A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients |
IL16507104A IL165071A0 (en) | 1990-03-30 | 2004-11-07 | The use of an mbp peptide for the preparation of amedicament for the treatment of multiple sclerosis |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL165071A IL165071A (en) | 1990-03-30 | 1991-03-28 | A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients |
IL16507104A IL165071A0 (en) | 1990-03-30 | 2004-11-07 | The use of an mbp peptide for the preparation of amedicament for the treatment of multiple sclerosis |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0522091B9 (de) |
JP (1) | JPH05507911A (de) |
AT (1) | ATE210721T1 (de) |
AU (1) | AU651350B2 (de) |
BR (1) | BR9106303A (de) |
CA (1) | CA2078549C (de) |
DE (1) | DE69132863T2 (de) |
DK (1) | DK0522091T5 (de) |
ES (1) | ES2169021T3 (de) |
HU (1) | HU217847B (de) |
IL (3) | IL97709A (de) |
NO (1) | NO308611B1 (de) |
WO (1) | WO1991015225A1 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207645B1 (en) | 1989-03-21 | 2001-03-27 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations |
US6221352B1 (en) | 1989-03-21 | 2001-04-24 | The Immune Response Corporation | Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells |
ES2090335T3 (es) * | 1990-05-01 | 1996-10-16 | Univ Leland Stanford Junior | Composiciones para uso en un metodo para tratar a un ser humano que padece esclerosis multiple. |
IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
JPH06507384A (ja) * | 1991-01-22 | 1994-08-25 | ザ イミューン レスポンス コーポレイション | 特定のt細胞群による病理的応答により生じる疾患に対するワクチン投与および方法 |
US5817629A (en) | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
US6252040B1 (en) | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
EP0623025A1 (de) * | 1991-12-24 | 1994-11-09 | The Immune Response Corporation | Impfung und therapie von krankheiten, die durch pathogene reaktionen spezifischer t-zellpopulationen hervorgerufen werden |
US5891435A (en) * | 1993-04-16 | 1999-04-06 | Research Corporation Technologies, Inc. | Methods and compositions for delaying or preventing the onset of autoimmune disease |
AU2950195A (en) * | 1994-07-01 | 1996-01-25 | Connective Therapeutics Inc. | Methods for diagnosing an immune-related disease and choosing an immune-related therapy |
IL115766A0 (en) * | 1994-10-25 | 1996-01-19 | Immulogic Pharma Corp | Composition and treatment for multiple sclerosis |
IL114458A0 (en) * | 1995-07-05 | 1995-11-27 | Yeda Res & Dev | Therapeutic preparations for treatment of T cell mediated diseases |
US6488933B2 (en) | 1995-07-05 | 2002-12-03 | Yeda Research And Development Co. Ltd. | Preparations for the treatment of T cell mediated diseases |
US20020009448A1 (en) * | 1997-09-19 | 2002-01-24 | Leslie P. Weiner | T-cell vaccination for the treatment of multiple sclerosis |
DE60129552T2 (de) | 2000-05-24 | 2008-04-17 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | E-selectin zur behandlung oder vorbeugung von schlaganfall |
CN102764425B (zh) * | 2000-08-21 | 2015-11-25 | 阿皮托普技术(布里斯托尔)有限公司 | 肽选择方法 |
US7658926B2 (en) | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
RU2004139045A (ru) * | 2002-06-05 | 2005-09-10 | Бейлор Колледж Оф Медисин (Us) | Последовательности cdr3 t-клеточного рецептора и способы детекции |
US7744893B2 (en) | 2002-06-05 | 2010-06-29 | Baylor College Of Medicine | T cell receptor CDR3 sequences associated with multiple sclerosis and compositions comprising same |
WO2004015070A2 (en) | 2002-08-08 | 2004-02-19 | Baylor College Of Medicine | Isolation and identification of t cells |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2072356A1 (en) * | 1989-12-29 | 1991-06-30 | James L. Urban | Diagnosis and treatment of diseases |
-
1991
- 1991-03-28 IL IL9770991A patent/IL97709A/xx not_active IP Right Cessation
- 1991-03-28 IL IL165071A patent/IL165071A/en not_active IP Right Cessation
- 1991-03-29 HU HU9203100A patent/HU217847B/hu unknown
- 1991-03-29 DK DK91910085T patent/DK0522091T5/da active
- 1991-03-29 WO PCT/US1991/002218 patent/WO1991015225A1/en active IP Right Grant
- 1991-03-29 AU AU78989/91A patent/AU651350B2/en not_active Expired
- 1991-03-29 DE DE69132863T patent/DE69132863T2/de not_active Expired - Lifetime
- 1991-03-29 BR BR919106303A patent/BR9106303A/pt not_active Application Discontinuation
- 1991-03-29 ES ES91910085T patent/ES2169021T3/es not_active Expired - Lifetime
- 1991-03-29 EP EP91910085A patent/EP0522091B9/de not_active Expired - Lifetime
- 1991-03-29 AT AT91910085T patent/ATE210721T1/de not_active IP Right Cessation
- 1991-03-29 JP JP91509347A patent/JPH05507911A/ja active Pending
- 1991-03-29 CA CA002078549A patent/CA2078549C/en not_active Expired - Lifetime
-
1992
- 1992-09-29 NO NO923778A patent/NO308611B1/no not_active IP Right Cessation
-
2004
- 2004-11-07 IL IL16507104A patent/IL165071A0/xx active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
BR9106303A (pt) | 1993-04-13 |
DK0522091T5 (da) | 2008-06-23 |
AU651350B2 (en) | 1994-07-21 |
IL97709A0 (en) | 1992-06-21 |
WO1991015225A1 (en) | 1991-10-17 |
HU217847B (hu) | 2000-04-28 |
ATE210721T1 (de) | 2001-12-15 |
HUT63334A (en) | 1993-08-30 |
NO923778L (no) | 1992-11-16 |
HU9203100D0 (en) | 1992-12-28 |
DE69132863T2 (de) | 2002-06-20 |
EP0522091B1 (de) | 2001-12-12 |
AU7898991A (en) | 1991-10-30 |
DK0522091T3 (da) | 2002-04-08 |
DE69132863D1 (de) | 2002-01-24 |
CA2078549A1 (en) | 1991-10-01 |
IL165071A0 (en) | 2005-12-18 |
NO308611B1 (no) | 2000-10-02 |
NO923778D0 (no) | 1992-09-29 |
IL165071A (en) | 2008-06-05 |
ES2169021T3 (es) | 2002-07-01 |
EP0522091A1 (de) | 1993-01-13 |
EP0522091B9 (de) | 2007-11-21 |
EP0522091A4 (en) | 1993-05-26 |
CA2078549C (en) | 2006-07-11 |
JPH05507911A (ja) | 1993-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL97709A (en) | Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis | |
GB2255093A (en) | Hiv-1 core protein fragments | |
IL128042A0 (en) | Immunological process for detecting antibodies directed towards tissue transglutaminase (ttg) use of ttg for diagnostic purposes and therapy control and oral pharmaceutical agent containing ttg | |
EP0474313A3 (en) | Nucleotide sequence coding for an outer membrane protein from neisseria meningitidis and use of said protein in vaccine preparations | |
PL311660A1 (en) | Viral vectors and their application in genic therapy | |
EP0600930A4 (de) | Diagnose und behandlung von autoimmunkrankheiten. | |
NL300156I1 (nl) | Therapeutische toepassing van chimere en radioactief gemerkte antilichamen tegen humane B-Lymfocyt beperkt differentiatie antigeen voor de behandelingvan B-Cel lymfoom. | |
GR3035440T3 (en) | Therapeutic uses of bpi protein products for human meningococcemia | |
GB2213823B (en) | Synthetic peptides for use in the diagnosis and prevention of influenza virus infection | |
DE69628844D1 (de) | Leishmania-antigene zur anwendung in der leishmaniasis therapie und diagnose | |
HUP0102479A2 (hu) | Neisseria meningitidis-ből származó BASBO29-polinukleotid(ok) és polipeptidek | |
GR3022092T3 (en) | Therapeutic method for iddm. | |
PT1025849E (pt) | Metodos para deteccao e tratamento de individuos tendo celulas anormais que expressam antigenios do peptideo hla-a2/tirosinase | |
EP0222310A3 (de) | Verfahren zur Diagnose von Multiple-Sklerose | |
ZA904565B (en) | Peptides and antibodies derived therefrom for the diagnosis of therapy for and vaccination against htlv-1 infection | |
NZ515332A (en) | Lawsonia derived gene and related SodC polypeptides, peptides and proteins and their uses | |
EP0601108A4 (en) | Multideterminant peptide antigens that stimulate helper t lymphocyte response to hiv in a range of human subjects. | |
NZ224251A (en) | Synthetic rhinovirus (hrv) peptides and vaccines | |
DE68918127D1 (de) | Peptidbehandlung von hartnäckigen Infektionskrankheiten. | |
AU2065488A (en) | The preparation of antigens of human immunodeficiency virus type 1, and the use thereof as diagnostic and therapeutic agent | |
杨春普 | ACUPUNCTURE OF GUANYUAN (REN 4) AND BAIHUI (DU 20) IN THE TREATMENT OF 500 CASES OF ENURESIS | |
FI963331A (fi) | Dermatophagoidesista (huonepölypunkeista) peräisin olevien pääasiallisten allergeenien T-soluepitoopit | |
GB9618119D0 (en) | Adjuvants for use in vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |